26Sep

Mylan Extends Commitment to Fight HIV/AIDS by Partnering with Atomo Diagnostics to Expand Access to HIV Self-Testing in Low- and Middle-Income Countries

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global
pharmaceutical company Mylan N.V. (NASDAQ: MYL) and medical device company Atomo
Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV
rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow
individuals to confidently screen themselves in the privacy of their own homes with a device
engineered for simplicity and accuracy. The tests are designed to detect the presence or
absence of HIV antibodies in a single drop of blood obtained from a fingertip. Results are
delivered in just 15 minutes, which is essential for access to early treatment and care.
A third of the 36.7 million people living with HIV are not aware of their status. While HIV testing
rates have improved, many countries still face obstacles in expanding access to testing, such as
patients being hard-to-reach or socially isolated due to stigma and discrimination. Deploying
point-of-care self-tests in community-based settings that deliver prompt and accurate results is
vital to increasing the proportion of people who know their HIV status. The sooner an individual
is tested, the sooner counseling can be offered and prevention options or treatment can be
initiated, which is critical to halting further transmission of the virus.
Mylan CEO Heather Bresch commented, “Today’s announcement is another great example of
our work to support the HIV/AIDS community, especially those living in low- and middle-income
countries. I am proud of Mylan’s efforts to fight HIV/AIDS around the world, which is part of our
long-standing commitment to increase access to treatment to address some of the world’s most
significant public health issues. Today, 40% of all people living with HIV who are receiving
treatment depend on antiretrovirals that we produce. But our work is far from over, with too
many new infections each year and too many people not receiving the care they need. Our
partnership with Atomo to supply HIV rapid diagnostic tests for self-testing is an important step
in our collective goal of preventing HIV infections and expanding treatment.”
Founder and CEO of Atomo Diagnostics John Kelly said, “We are delighted that our innovative
HIV self-tests have been chosen by Mylan, the global health leader in HIV treatment and the
largest supplier of ARVs. This strategic partnership will mean that the products designed by
Atomo can be introduced to more than 100 countries, so that millions of people will have access
to award-winning rapid tests. We believe that Mylan is the ideal partner to ensure that our HIV
self-test products have maximum impact in the fight against HIV/AIDS.”
While in some countries, like the U.S. and in Europe, HIV self-tests are readily available in
pharmacies, HIV testing in low- and middle-income countries remains dependent on the
diagnostic test being conducted in formal settings by trained professionals. Scaling up selftesting
globally requires a simple and reliable product. Atomo is partnering with Mylan to supply
all-in-one test devices that offer improved functionality and ease-of-use compared to current
multi-component rapid diagnostic tests.
Atomo products are highly accurate. In laboratory and in-field evaluations, Atomo diagnostic
tests demonstrated an aggregated 99.6% for sensitivity and specificity. Atomo HIV self-test
products are CE-marked and are being evaluated by the World Health Organization for
prequalification.
Under the terms of the agreement, Mylan has exclusive rights to commercialize the products in
more than 100 countries in Africa, Asia, the Middle East, the Commonwealth of Independent
States (CIS) and Latin America. Mylan plans to launch the Mylan HIV Self-Test in global
markets in early 2019.
Mylan's Commitment to the HIV/AIDS Patient Community
Mylan is the world's largest supplier by volume of HIV/AIDS therapies. More than 40% of the 20
million patients on treatment worldwide depend on a Mylan product every day. For more than a
decade, Mylan has been a leader in providing access to quality, dependable and affordable
ARVs in 100 countries around the world. This includes introducing in 2009 the first generic onetablet-
once-a-day combination for developing countries – only three years after the originator
product launched in the U.S. Since that time, Mylan has been the first to market with nearly half
of the new products tentatively approved by the FDA under PEPFAR. Mylan was also the first
generic drug maker to develop a heat-stable version of a drug critical for second-line regimens
and has consistently developed innovative pediatric formulations for children in developing
countries. Mylan has long been a supporter of the patient community through the sponsorship of
free community HIV/AIDS testing and clinical research. Learn more about Mylan's work with
infectious disease here. Watch this video to learn more about Mylan's commitment to people
living with HIV/AIDS.
This press release includes statements that constitute "forward-looking statements", including
with regard to Mylan planning to launch the Mylan HIV Self-Test in global markets in early 2019.
These statements are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Because such statements inherently involve risks and
uncertainties, actual future results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such differences include,
but are not limited to: success of clinical trials and our or our partners' ability to execute on new
product opportunities; any regulatory, legal or other impediments to our or our partners' ability to
bring products to market; other risks inherent in product development; the scope, timing, and
outcome of any ongoing legal proceedings, including government investigations, and the impact
of any such proceedings on our or our partners' businesses; actions and decisions of healthcare
and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and
regulations, in the United States and abroad; the impact of competition; strategies by
competitors or other third parties to delay or prevent product introductions; the effect of any
changes in our or our partners' customer and supplier relationships and customer purchasing
patterns; any other changes in third-party relationships; changes in the economic and financial
conditions of the businesses of Mylan or its partners; uncertainties and matters beyond the
control of management; and the other risks detailed in Mylan's filings with the Securities and
Exchange Commission. Mylan undertakes no obligation to update these statements for
revisions or changes after the date of this release.
About Mylan
Mylan is a global pharmaceutical company committed to setting new standards in healthcare.
Working together around the world to provide 7 billion people access to high quality medicine,
we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's
right, not what's easy; and impact the future through passionate global leadership. We offer a
growing portfolio of more than 7,500 marketed products around the world, including
antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally
depend. We market our products in more than 165 countries and territories. We are one of the
world's largest producers of active pharmaceutical ingredients. Every member of our
approximately 35,000-strong workforce is dedicated to creating better health for a better world,
one person at a time. Learn more at Mylan.com. We routinely post information that may be
important to investors on our website at investor.mylan.com.
About Atomo Diagnostics
Atomo Diagnostics is a world leader in medical device design and development, based in
Sydney, Australia. The company specialises in pioneering rapid diagnostic test (RDT) solutions
for use with capillary blood samples.
The recipient of multiple international awards for innovation, AtomoRapid™ device platforms put
the end user first and make it easy to test and screen for a range of infectious diseases and
chronic conditions. Unlike standard, multi-component rapid test kits, Atomo’s all-in-one
platforms integrate features and functionality, incorporating a sterile safety lancet, calibrated
blood collection system, and unique buffer delivery mechanism.
Atomo provides OEM product development services to specialist diagnostic companies
worldwide, as well as commercialising products in its own brand. To find out more,
visit http://atomodiagnostics.com/oem/
For queries please contact –
Mylan Atomo Diagnostics
Christine Waller (Media)
724.514.1968
Email: communications@mylan.com
Melissa Trombetta (Investors)
724.514.1813
Email: InvestorRelations@mylan.com
John Kelly
+61 (0)2 9099 4750
Email: john.kelly@atomodiagnostics.com

Related

Cytox appoints new CCO

Oxford and Manchester, UK – Cytox, a precision medicine company focused on developing solutions to ...

Read More >

BBI Solutions Increases Capacity for Cell Culture Native Human Transferrin Production

BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity ...

Read More >

BBI Solutions & Dr C. Sturgeon consider International Standards for Cancer Biomarkers

Dr Catharine Sturgeon will be presenting her case for an international effort to align manufacturer’...

Read More >

BBI Solutions adds more antibodies to product range

BBI Solutions has continued to invest in its portfolio of antibodies and today announced the launch ...

Read More >

New Multiplex Real-time PCR Kits Detect Clinically Relevant β-lactamase Genes

β-lactamase enzymes inactivate β-lactam antibiotics and render them ineffective for the treatment ...

Read More >

Radiometer helps enhance patient outcomes at the University of Leicester Hospitals NHS Trust

Crawley, UK – 15 February 2018 – Radiometer Ltd has implemented its AQURE Enterprise point-of-care...

Read More >